The safety of istradefylline for the treatment of Parkinson’s disease

Bibliography

• HPrzuntek, TMüller, PRiederer. Diagnostic staging of Parkinson’s disease: conceptual aspects. J.Neural Transm 2004;111(2):201-16
   PubMed Web of Science ®Google Scholar
• TMüller. Catechol-O-Methyltransferase inhibitors in parkinson’s disease. Drugs 2015;75(2):157-74
   PubMed Web of Science ®Google Scholar
• TMüller. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener 2012;1(1):1-10
   PubMedGoogle Scholar
• LVKalia, JMBrotchie, SHFox. Novel nondopaminergic targets for motor features of Parkinson’s disease: review of recent trials. Mov Disord 2013;28(2):131-44
   PubMed Web of Science ®Google Scholar
• MRivera-Oliver, MAz-Rios. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci 2014;101(1-2):1-9
   PubMed Web of Science ®Google Scholar
• VHarvey, JJones, AMisra, et al. Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors. Eur J Pharmacol 2001;431(2):171-7
   PubMed Web of Science ®Google Scholar
• PHickey, MStacy. Adenosine A2A antagonists in Parkinson’s disease: what’s next? Curr.Neurol Neurosci Rep 2012;12(4):376-85
   PubMed Web of Science ®Google Scholar
• PJenner, AMori, RHauser, et al. Adenosine, adenosine A2A antagonists, and Parkinson’s disease. Parkinsonism Relat Disord 2009;15(6):406-13
   PubMed Web of Science ®Google Scholar
• KABennett, BTehan, GLebon, et al. Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. Mol Pharmacol 2013;83(5):949-58
   PubMed Web of Science ®Google Scholar
• JFChen, KXu, JPPetzer, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci 2001;21(10):RC143
   PubMed Web of Science ®Google Scholar
• LECollins, DJGaltieri, PCollins, et al. Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: effects on locomotor activity. Behav Brain Res 2010;211(2):148-55
   PubMed Web of Science ®Google Scholar
• VPerez, VSosti, ARubio, et al. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol 2007;576(1-3):83-90
   PubMed Web of Science ®Google Scholar
• BFloran, CBarajas, LFloran, et al. Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neuroscience 2002;115(3):743-51
   PubMed Web of Science ®Google Scholar
• PPopoli, LGimenez-Llort, APezzola, et al. Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents. Neurosci Lett 1996;218(3):209-13
   PubMed Web of Science ®Google Scholar
• SFerre, PPopoli, BTinner-Staines, et al. Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites. Neurosci Lett 1996;208(2):109-12
   PubMed Web of Science ®Google Scholar
• EPourcher, HHFernandez, MStacy, et al. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord 2012;18(2):178-84
   PubMed Web of Science ®Google Scholar
• MStacy, DSilver, TMendis, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70(23):2233-40
   PubMed Web of Science ®Google Scholar
• RKartzinel, IShoulson, DBCalne. Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology 1976;26(8):741-3
   PubMed Web of Science ®Google Scholar
• IShoulson, TChase. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology 1975;25(8):722-4
   PubMed Web of Science ®Google Scholar
• MKitagawa, HHouzen, KTashiro. Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord 2007;22(5):710-12
   PubMed Web of Science ®Google Scholar
• RBPostuma, AELang, RPMunhoz, et al. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology 2012;79(7):651-8
   PubMed Web of Science ®Google Scholar
• RAHauser, CWOlanow, KDKieburtz, et al. Tozadenant (SYN115) in patients with Parkinson’s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol 2014;13(8):767-76
   PubMed Web of Science ®Google Scholar
• RHauser, FStocchi, ORascol, et al. Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease. Neurology 2014;82(10 Suppl):P7.087
   Google Scholar
• NRao, BDvorchik, NSussman, et al. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson’s disease, and atorvastatin. J Clin Pharmacol 2008;48(9):1092-8
   PubMed Web of Science ®Google Scholar
• NRao. Re: efflux transporter-mediated interactions with atorvastatin–interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. J Clin Pharmacol 2011;51(5):784
   PubMedGoogle Scholar
• FBibbiani, JDOh, JPPetzer, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson’s disease. Exp Neurol 2003;184(1):285-94
   PubMed Web of Science ®Google Scholar
• JFChen, SFredduzzi, EBastia, et al. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson’s disease. Neurology 2003;61(11 Suppl 6):S74-81
   PubMedGoogle Scholar
• RGrondin, PJBedard, TAHadj, et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999;52(8):1673-7
   PubMed Web of Science ®Google Scholar
• HKase, SAoyama, MIchimura, et al. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease. Neurology 2003;61(11 Suppl 6):S97-100
   PubMedGoogle Scholar
• MOrru, JBakesova, MBrugarolas, et al. Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists. PLoS One 2011;6(1):e16088
   PubMed Web of Science ®Google Scholar
• WKnebel, NRao, TUchimura, et al. Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson’s disease. J Clin Pharmacol 2011;51(1):40-52
   PubMed Web of Science ®Google Scholar
• WKnebel, NRao, TUchimura, et al. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol 2012;52(10):1468-81
   PubMed Web of Science ®Google Scholar
• TNChase, FBibbiani, WBara-Jimenez, et al. Translating A2A antagonist KW6002 from animal models to parkinsonian patients. Neurology 2003;61(11 Suppl 6):S107-11
   PubMedGoogle Scholar
• MLundblad, EVaudano, MACenci. Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem 2003;84(6):1398-410
   PubMed Web of Science ®Google Scholar
• MLundblad, AUsiello, MCarta, et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp Neurol 2005;194(1):66-75
   PubMed Web of Science ®Google Scholar
• DXiao, EBastia, YHXu, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. J Neurosci 2006;26(52):13548-55
   PubMed Web of Science ®Google Scholar
• WChen, HWang, HWei, et al. Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson’s Disease: a meta-analysis. J Neurol Sci 2013;324(1-2):21-8
   PubMed Web of Science ®Google Scholar
• YTao, GLiang. Efficacy of Adenosine A2A receptor antagonist istradefylline as augmentation for parkinson’s disease: a meta-analysis of randomized controlled trials. Cell BiochemBiophys 2015;71(1):57-62
   Google Scholar
• CZhu, GWang, JLi, et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis. Neurol Res 2014;36(11):1028-34
   PubMed Web of Science ®Google Scholar
• CWOlanow, KKieburtz, ORascol, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013;28(8):1064-71
   PubMed Web of Science ®Google Scholar
• CJBleickardt, ALLashomb, CEMerkel, et al. Adenosine A2A receptor antagonists do not disrupt rodent prepulse inhibition: an improved side effect profile in the treatment of parkinson’s disease. Parkinsons Dis 2012;2012:591094
   PubMed Web of Science ®Google Scholar
• RAHauser, JPHubble, DDTruong. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003;61(3):297-303
   PubMed Web of Science ®Google Scholar
• RAHauser, LMShulman, JMTrugman, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 2008;23(15):2177-85
   PubMed Web of Science ®Google Scholar
• PALeWitt, MGuttman, JWTetrud, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302
   PubMed Web of Science ®Google Scholar
• YMizuno, KHasegawa, TKondo, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord 2010;25(10):1437-43
   PubMed Web of Science ®Google Scholar
• APark, MStacy. Istradefylline for the treatment of Parkinson’s disease. Expert Opin Pharmacother 2012;13(1):111-14
   PubMed Web of Science ®Google Scholar
• CJugel, FEhlen, BTaskin, et al. Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 2013;8(6):e66639
   PubMed Web of Science ®Google Scholar
• JFMorley, JEDuda. Parkinson’s disease and the risk of cerebrovascular pathology. Mov Disord 2012;27(12):1471-2
   PubMed Web of Science ®Google Scholar
• TMüller. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother 2013;13(6):707-18
   PubMed Web of Science ®Google Scholar
• TMüller, LTvan, DRCornblath, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19(5):501-7
   PubMed Web of Science ®Google Scholar
• IRektor, DGoldemund, PBednarik, et al. Impairment of brain vessels may contribute to mortality in patients with Parkinson’s disease. Mov Disord 2012;27(9):1169-72
   PubMed Web of Science ®Google Scholar
• RSSchwartz, GMHalliday, DJCordato, et al. Small-vessel disease in patients with Parkinson’s disease: a clinicopathological study. Mov Disord 2012;27(12):1506-12
   PubMed Web of Science ®Google Scholar
• RGray, NIves, CRick, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014;384(9949):1196-205
   PubMed Web of Science ®Google Scholar
• FPedata, AMPugliese, AMelani, et al. A2A receptors in neuroprotection of dopaminergic neurons. Neurology 2003;61(11 Suppl 6):S49-50
   PubMedGoogle Scholar
• MPierri, EVaudano, TSager, et al. KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology 2005;48(4):517-24
   PubMed Web of Science ®Google Scholar
• NSzabo, ZTKincses, LVecsei. Novel therapy in Parkinson’s disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011;7(4):441-55
   PubMed Web of Science ®Google Scholar
• HPrzuntek, BConrad, JDichgans, et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999;6(2):141-50
   PubMed Web of Science ®Google Scholar